Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Conditioning Regimens

Reliability of a pretransplant i.v. BU test dose performed 2 weeks before myeloablative FluBu conditioning regimen

Bone Marrow Transplantation volume 45, pages 249–253 (2010)Cite this article

Abstract

A pretransplant test dose of i.v. BU was previously used in pediatric patients undergoing a reduced-intensity allogeneic hematopoietic SCT (HSCT). Here, we used a BU test dose in 23 adult patients who were not pancytopenic and underwent a myeloablative allogeneic HSCT prepared with fludarabine and i.v. BU (FluBU). Pharmacokinetics (PK) of BU were calculated after a test dose (0.8 mg/kg) was performed 2 weeks before transplant. Targeted BU area under the curve (AUC) range was 4800–5200 μM min. The mean BU dose calculated after the test dose was 3.5±0.5 mg/kg. To validate the test dose, PK studies were repeated in 17 patients after the first dose of BU during the conditioning regimen. An AUC below the therapeutic value of 4000 μM min was observed in 23% of the patients receiving a wt-based dose and in 0% of patients whose dose was calculated on the basis of the test dose (P=0.03). In patients who had a test dose, a significant correlation (P<0.0001) between the first and subsequent doses of BU during the conditioning regimen was observed. Our findings may allow more centers to pursue transplant strategies with targeted BU by overcoming the time limitation for PK studies during the conditioning regimen.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3

Similar content being viewed by others

References

  1. Bornhauser M, Storer B, Slattery JT, Appelbaum FR, Deeg HJ, Hansen J et al. Conditioning with fludarabine and targeted busulfan for transplantation of allogeneic hematopoietic stem cells. Blood 2003; 102: 820–826.

    Article  PubMed  Google Scholar 

  2. Deeg HJ, Gooley TA, Flowers ME, Sale GE, Slattery JT, Anasetti C . Allogeneic hematopoietic stem cell transplantation for myelofibrosis. Blood 2003; 102: 3912–3918.

    Article  CAS  PubMed  Google Scholar 

  3. Anderson BS, Madden T, Tran HT, Hu WW, Blume KG, Chow DS . Acute safety and pharmacokinetics of intravenous busulfan when used with oral busulfan and cyclophosphamide as pretransplantation conditioning therapy: a phase I study. Biol Blood Marrow Transplant 2000; 6: 548–554.

    Article  Google Scholar 

  4. Fernandez HF, Tran HT, Federico A, Lennon S, Caldera H, Goodman MS . Evaluation of safety and pharmacokinetics of administering intravenous busulfan in a twice daily or daily schedule to patients with advanced hematology malignant disease undergoing stem cell transplantation. Biol Blood Marrow Transplant 2002; 8: 486–492.

    Article  CAS  PubMed  Google Scholar 

  5. Madden T, De Lima M, Thapar N, Nguyen J, Roberson S, Couriel D . Pharmacokinetics of once daily IV busulfan as part of pretransplantation preparative regimens: a comparison with an every 6 h dosing schedule. Biol Blood Marrow Transplant 2007; 13: 56–64.

    Article  CAS  PubMed  Google Scholar 

  6. Russell JA, Tran HT, Quinlan D, Chaudhry A, Duggan P, Brown C . Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes. Biol Blood Marrow Transplant 2002; 8: 468–476.

    Article  CAS  PubMed  Google Scholar 

  7. de Lima M, Couriel D, Thall PF, Wang X, Madden T, Jones R . Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS. Blood 2004; 104: 857–864.

    Article  CAS  PubMed  Google Scholar 

  8. Kangarloo S, Naveed F, Anderson B . Individualized once daily dosing of intravenous Busulfan: a pharmacokinetic study in patients undergoing conditioning for allogeneic stem cell transplantation. Biol Blood Marrow Transplant 2005; Tandem BMT meeting, Abstract no. 98.

  9. Andersson BS, Kashyap A, Gian V, Wingard JR, Fernandez H, Cagnoni PJ . Conditioning therapy with intravenous busulfan and cyclophosphamide (IV BuCy2) for hematologic malignancies prior to allogeneic stem cell transplantation: a phase II study. Biol Blood Marrow Transplant 2002; 8: 145–154.

    Article  CAS  PubMed  Google Scholar 

  10. Chunduri S, Dobogai LC, Peace D, Saunthararajah Y, Chen HY, Mahmud N et al. Comparable kinetics of myeloablation between fludarabine/full-dose busulfan and fludarabine/melphalan conditioning regimens in allogeneic peripheral blood stem cell transplantation. Bone Marrow Transplant 2006; 38: 477–482.

    Article  CAS  PubMed  Google Scholar 

  11. Chunduri S, Dobogai LC, Peace D, Saunthararajah Y, Quigley J, Chen YH et al. Fludarabine/I.V. BU conditioning regimen: myeloablative, reduced intensity or both? Bone Marrow Transplant 2008; 41: 935–940.

    Article  CAS  PubMed  Google Scholar 

  12. Dix SP, Wingard JR, Mullins RE, Jerkunica I, Davidson TG, Gilmore CE . Association of busulfan area under the curve with veno-occlusive disease following BMT. Bone Marrow Transplant 1996; 17: 225–230.

    CAS  PubMed  Google Scholar 

  13. Kletzel M, Jacobsohn D, Duerst R . Pharmacokinetics of test dose of intravenous Busulfan guide dose modifications to achieve an optimal area under the curve of a single daily dose of intravenous Busulfan in children undergoing a reduced intensity conditioning regimen with hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2006; 12: 472–479.

    CAS  PubMed  Google Scholar 

  14. Chan KW, Mullen CA, Worth LL, Choroszy M, Koontz S, Tran H . Lorazepam for seizure prophylaxis during high-dose busulfan administration, Bone Marrow Transplant. 2002; 29: 963–965.

  15. McCune JS, Gibbs JP, Slattery JT . Plasma concentration monitoring of busulfan: does it improve clinical outcome? Clin Pharmacokinet 2000; 39: 155–165.

    Article  CAS  PubMed  Google Scholar 

  16. Hassan M, Oberg G, Ehrsson H, Ehrnebo M, Wallin I, Smedmyr B et al. Pharmacokinetic and metabolic studies of high-dose busulphan in adults. Eur J Clin Pharmacol 1989; 36: 525–530.

    Article  CAS  PubMed  Google Scholar 

  17. Hassan M, Ljungman P, Bolme P, Ringdén O, Syrůcková Z, Békàssy A et al. Busulfan bioavailability. Blood 1994; 84: 2144–2150.

    CAS  PubMed  Google Scholar 

  18. Li X, Ruiz CH, Koenig M, Cameron MD . Characterization of dasatinib and its structural analogs as CYP3A4 mechanism based inactivators and the proposed bio-activation pathways. Drug Metab Dispos 2009; 37: 1242–1250.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Russell JA, Kangarloo SB . Therapeutic drug monitoring of busulfan in transplantation. Curr Pharm Des 2008; 14: 1936–1949.

    Article  CAS  PubMed  Google Scholar 

  20. Vaughan WP, Carey D, Perry S, Westfall AO, Salzman DE . A limited sampling strategy for pharmacokinetic directed therapy with intravenous busulfan. Biol Blood Marrow Transplant 2002; 8: 619–624.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pharmacy Practice, University of Illinois at Chicago, Chicago, IL, USA

    R Beri, K Sweiss, C Mactal-Haaf & S Shord

  2. Section of Hematology Oncology, University of Illinois at Chicago, Chicago, IL, USA

    S Chunduri, D J Peace, L C Dobogai, J G Quigley, Y H Chen, N Mahmud & D Rondelli

  3. UIC Cancer Center, University of Illinois at Chicago, Chicago, IL, USA

    D J Peace, J G Quigley, Y H Chen, N Mahmud & D Rondelli

Authors
  1. R Beri
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. S Chunduri
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. K Sweiss
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. D J Peace
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. C Mactal-Haaf
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. L C Dobogai
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. S Shord
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. J G Quigley
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Y H Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. N Mahmud
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. D Rondelli
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to D Rondelli.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Beri, R., Chunduri, S., Sweiss, K. et al. Reliability of a pretransplant i.v. BU test dose performed 2 weeks before myeloablative FluBu conditioning regimen. Bone Marrow Transplant 45, 249–253 (2010). https://doi.org/10.1038/bmt.2009.133

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2009.133

Keywords

This article is cited by

Search

Advanced search

Quick links